Dr. Yves Pommier Chief of the Developmental Therapeutics Branch and Head of the Molecular Pharmacology Group at the National Cancer Institute. With permission of the NCI, he is an unpaid Special Consultant, working closely with Gibson Oncology leadership to advance clinical development of the Indenoisoquinolines. He is a world expert on DNA topoisomerase biology and biochemistry, and their cancer relevance. He and his team uncovered the molecular mechanisms of topoisomerase inhibitors. Working with Dr. Mark Cushman of Purdue, he discovered the indenoisoquinolines as novel Top1 inhibitors and Dr. Pommier’s laboratory has been responsible for their pre-clinical development and has participated in the design of the five NCI phase I clinical trials conducted to date.
Gibson Oncology,LLC is composed of proven academic researchers and bio tech entrepreneurs who are excited to be developing effective and safer novel oncology drugs to treat resistant cancers with a focus on children.